Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,196 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07683403 | Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer | not yet recruiting | Phase 1 / Phase 2 | 138 | Fudan UniversityOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04766515 | Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms | recruiting | — | 6,000 | Fudan UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05541783 | Laparoscopic-assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy for Gastric Cancer | completed | N/A | 213 | Fudan UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07673835 | Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer(Phase II) | not yet recruiting | Phase 2 | 49 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05479409 | Neoadjuvant Radiation in Locally Advanced Breast Cancer | recruiting | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07669610 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC(TRIBE) | not yet recruiting | Phase 3 | 140 | Fudan UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07666555 | A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy. | recruiting | Phase 2 | 98 | Fudan UniversityOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07662863 | Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)(SPARE-UC-01) | not yet recruiting | Phase 2 | 75 | Fudan UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07663513 | Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer | not yet recruiting | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06263205 | Non-Dressing vs. Routine Dressing Change After Gastrointestinal Cancer Surgery(Dressing) | completed | N/A | 1,138 | Fudan UniversityOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07656324 | Epidemiology and Prognostic Analysis of Chinese Cancer Patients With Cancer-related Fatigue | recruiting | — | 1,000,000 | Fudan UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07652489 | Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma: A Prospective Observational Study(SPORT-SNACC) | recruiting | — | 70 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07653893 | A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer(BCBM006) | recruiting | — | 60 | Fudan UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07649174 | Cadonilimab Plus Chemotherapy in LACC: A Prospective, Multicenter, Randomized Phase II Trial | not yet recruiting | Phase 2 | 134 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07557654 | Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT(OPBCS-CT) | recruiting | — | 5,000 | Fudan UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647016 | Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study | recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647029 | A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae(PROTECT) | not yet recruiting | Phase 2 | 126 | Fudan UniversityOTHER | 0 | Jun 15, 2026 | clinicaltrials |
| NCT05384444 | Effect of FMD on Colorectal Cancer Patients(FCRC22) | active not recruiting | N/A | 602 | Fudan UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07638774 | The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy. | recruiting | N/A | 324 | Fudan UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07628504 | Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations(STARTER) | not yet recruiting | Phase 3 | 420 | Fudan UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05247268 | Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer | recruiting | Phase 2 | 104 | Fudan UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06914297 | TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC | recruiting | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07612436 | AI-empowered Nudge to Improve Colonoscopy Uptake (AINC) | not yet recruiting | N/A | 1,680 | Fudan UniversityOTHER | 0 | Jun 4, 2026 | clinicaltrials |
| NCT07626021 | Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms | not yet recruiting | Phase 2 | 15 | Zhongshan Hospital (Xiamen), Fudan UniversityOTHER | 0 | Jun 4, 2026 | clinicaltrials |
| NCT07626177 | Association Between Screening Behaviors and Lung Cancer Spectrum | recruiting | — | 5,390 | Fudan UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07622862 | Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM) | not yet recruiting | Phase 1 | 16 | Zhongshan Hospital (Xiamen), Fudan UniversityOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07623577 | Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases | recruiting | Phase 2 | 24 | Fudan UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07619911 | SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 84 | Fudan UniversityOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT07616141 | Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma(NAET4-SNACC) | not yet recruiting | Phase 2 | 76 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07615751 | Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer | recruiting | Phase 3 | 502 | Fudan UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05582499 | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy(FASCINATE-N) | recruiting | Phase 2 | 716 | Fudan UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07610733 | Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients.(IFOCOS) | not yet recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 0 | May 28, 2026 | clinicaltrials |
| NCT04296162 | Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)(ORCHID) | completed | Phase 2 | 182 | Fudan UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05774275 | The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma(RAPID) | recruiting | Phase 1 / Phase 2 | 52 | Fudan UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06427239 | Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 130 | Fudan UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07557849 | Multicentric Database for KRAS Mutant Pancreatic Cancer | recruiting | — | 1,000 | Fudan UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07605663 | an AI-Driven Four-Tier Invasion Depth Classification for Early Esophageal Cancer | active not recruiting | — | 890 | Fudan UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07604909 | A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy | recruiting | Phase 2 | 40 | Fudan UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03245346 | Effects of Epidural Anesthesia and Analgesia on the Prognosis in Patients Undergoing Pancreatic Cancer Surgery | completed | N/A | 540 | Fudan UniversityOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07592663 | Oncologic Safety and Lymphadenectomy in Parenchyma-Sparing Resection for SPN(PSR for SPN) | completed | — | 708 | Fudan UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06591650 | Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer(GCND) | recruiting | Phase 2 | 33 | Fudan UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07583927 | Anemia on Sublingual Microcirculation in GDFT | enrolling by invitation | — | 54 | Fudan UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07320508 | Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study(EIC-SNACC) | recruiting | Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07563088 | SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma(SPARE-1st) | not yet recruiting | — | 200 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581795 | Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer(SPECTACLE) | not yet recruiting | Phase 2 | 140 | Fudan UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07574749 | Molecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic Efficacy | recruiting | — | 1,500 | Fudan UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07573397 | A Prospective Study of Tumor-specific Tpex in Negative Lymph Nodes for Predicting Pathological Complete Response to Neoadjuvant PD 1 Therapy in Esophageal Cancer | not yet recruiting | — | 88 | Fudan UniversityOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT07561060 | Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy(TNTIT) | recruiting | Phase 1 / Phase 2 | 50 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562490 | A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer(CLEAR-04) | recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562503 | Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer(CLEAR-03) | recruiting | Phase 2 | 340 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials